VitriVax raises $17.25M Series B financing to advance vaccine formulation platform
University of Colorado Boulder spinout VitriVax has raised $17.25 million in Series B financing to accelerate development of its Stablevaxâ„¢ platform, which eliminates the need for cold storage in vaccines. The funding will support preclinical and clinical advancement of single-dose, thermostable vaccines aimed at improving global immunization access.
The University of Colorado Connection
VitriVax is a biotechnology company working to eliminate barriers to global vaccination, and has developed a novel stabilization and delivery platform for vaccines and therapeutics based on research in the laboratories of (¶¶ÒõÂÃÐÐÉä Boulder Molecular, Cellular & Developmental Biology) and Ìýat ¶¶ÒõÂÃÐÐÉä Boulder (¶¶ÒõÂÃÐÐÉä Boulder Chemical and Biological Engineering).
The Newsroom
For marketing and communication inquiries or news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at ¶¶ÒõÂÃÐÐÉä Boulder.
For media inquiries, please visit .